Hal Atkinson to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Hal Atkinson has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.230
-
Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med. 2009 Jul 13; 169(13):1195-202.
Score: 0.080
-
Cesari M, Kritchevsky SB, Atkinson HH, Penninx BW, Di Bari M, Tracy RP, Pahor M. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb; 157(2):334.e1-8.
Score: 0.077
-
Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M. Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005 Aug; 82(2):428-34.
Score: 0.060
-
Onder G, Penninx BW, Landi F, Atkinson H, Cesari M, Bernabei R, Pahor M. Depression and adverse drug reactions among hospitalized older adults. Arch Intern Med. 2003 Feb 10; 163(3):301-5.
Score: 0.013